Holen Sie sich die Stockscreener-App
7.23
2.26%
0.16
Handel nachbörslich:
7.23
Schlusskurs vom Vortag:
$7.07
Offen:
$7.07
24-Stunden-Volumen:
137.81K
Relative Volume:
2.54
Marktkapitalisierung:
$24.20M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-14.56M
KGV:
-0.4298
EPS:
-16.82
Netto-Cashflow:
$-12.46M
1W Leistung:
+20.50%
1M Leistung:
+12.79%
6M Leistung:
+77.64%
1J Leistung:
-49.30%
1-Tages-Spanne:
$7.07
$7.33
1-Wochen-Bereich:
$5.85
$7.33
52-Wochen-Spanne:
$2.77
$7.33
Tenax Therapeutics Inc Stock (TENX) Company Profile
Firmenname
Tenax Therapeutics Inc
Sektor
Branche
Telefon
919-855-2100
Adresse
101 GLEN LENNOX DRIVE, CHAPEL HILL, NC
Vergleichen Sie TENX mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
TENX
Tenax Therapeutics Inc
|
7.23 | 24.20M | 0 | -14.56M | -12.46M | -16.82 |
|
VRTX
Vertex Pharmaceuticals Inc
|
469.32 | 122.13B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
710.00 | 78.30B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
646.64 | 39.73B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
276.19 | 35.50B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
117.61 | 28.47B | 3.30B | -501.07M | 1.03B | -2.1146 |
Tenax Therapeutics Inc Stock (TENX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2024-10-24 | Eingeleitet | Leerink Partners | Outperform |
| 2024-10-14 | Eingeleitet | Guggenheim | Buy |
| 2024-09-30 | Eingeleitet | William Blair | Outperform |
| 2017-05-18 | Hochstufung | Ladenburg Thalmann | Neutral → Buy |
| 2014-12-16 | Eingeleitet | MLV & Co | Buy |
| 2014-11-18 | Eingeleitet | WallachBeth | Buy |
Alle ansehen
Tenax Therapeutics Inc Aktie (TENX) Neueste Nachrichten
Leerink Partnrs Weighs in on TENX FY2029 Earnings - Defense World
David Risinger Recommends Buy for Tenax Therapeutics Amid Promising Phase 3 Trials and Growth Potential - TipRanks
Tenax Therapeutics (NASDAQ:TENX) Share Price Passes Above 200-Day Moving Average – What’s Next? - Defense World
Tenax Therapeutics to Participate in the Guggenheim SMID Cap Biotech Conference - GlobeNewswire
Exclusive: Tenax CEO to Reveal Latest Cardiovascular Drug Pipeline Updates at Major Biotech Conference - StockTitan
Trump's Federal Spending Freeze Puts $3 Trillion In Limbo, Threatens Industries Like Clean Energy, Defense, Health Care - Benzinga
Tenax Therapeutics (NASDAQ:TENX) Stock Price Crosses Above 200 Day Moving Average – What’s Next? - Defense World
Tenax Therapeutics appoints new VP of Clinical Operations - MSN
Tenax Therapeutics Appoints Gillian Andor Vice President, Clinical Operations - The Manila Times
Analysts Set Tenax Therapeutics, Inc. (NASDAQ:TENX) Target Price at $16.00 - Defense World
PH balance: Tenax outweighs pharmas with levosimendan heart bid - BioWorld Online
Tenax Therapeutics (NASDAQ:TENX) Share Price Crosses Above 200-Day Moving Average – Here’s Why - Defense World
Comparing Merus (NASDAQ:MRUS) & Tenax Therapeutics (NASDAQ:TENX) - Defense World
Tenax Therapeutics, Inc. (NASDAQ:TENX) Receives $16.00 Consensus Target Price from Analysts - Defense World
Tenax Therapeutics, Inc. Appoints Thomas A. McGauley as Principal Financial Officer and Principal Accounting Officer - Marketscreener.com
Biotech Soars Following Oversubscribed $100M Private Placement Announcement - MSN
Will Tenax Therapeutics (NASDAQ:TENX) Spend Its Cash Wisely? - Yahoo Finance
Is Tenax Therapeutics (NASDAQ:TENX) In A Good Position To Invest In Growth? - Simply Wall St
Tenax Therapeutics Appoints Interim CFO Thomas McGauley - TipRanks
Tenax Therapeutics: Q3 Earnings Snapshot - New Haven Register
Tenax Therapeutics Reports Third Quarter 2024 Financial Results and Provides a Corporate Update - The Manila Times
Tenax Therapeutics Secures $100M Funding, Extends Runway to 2027 Despite Wider Q3 Loss | TENX Stock News - StockTitan
Tenax Therapeutics (NASDAQ:TENX) Stock Price Passes Above 200-Day Moving Average – Here’s Why - Defense World
Tenax Therapeutics to Present at the Guggenheim Healthcare Innovation Conference - The Manila Times
Tenax Therapeutics expands stock incentive plan By Investing.com - Investing.com Australia
Tenax Therapeutics expands stock incentive plan - Investing.com
Tenax Therapeutics Expands Stock Incentive Plan - TipRanks
Analysts Set Tenax Therapeutics, Inc. (NASDAQ:TENX) Target Price at $170.67 - Defense World
FY2024 Earnings Estimate for TENX Issued By Leerink Partnrs - Defense World
Tenax Therapeutics (NASDAQ:TENX) Coverage Initiated at Leerink Partners - Defense World
Leerink Partnrs Upgrades Tenax Therapeutics (NASDAQ:TENX) to “Strong-Buy” - Defense World
This Sempra Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Thursday - Benzinga
Warning: TENX is at high risk of performing badly - MSN
Guggenheim Initiates Coverage of Tenax Therapeutics (TENX) with Buy Recommendation - Nasdaq
Tenax Therapeutics, Inc. to Post Q3 2024 Earnings of ($1.50) Per Share, William Blair Forecasts (NASDAQ:TENX) - Defense World
William Blair Initiates Coverage of Tenax Therapeutics (TENX) with Outperform Recommendation - MSN
SEC Form DEF 14A filed by Tenax Therapeutics Inc. - Quantisnow
StockNews.com Initiates Coverage on Tenax Therapeutics (NASDAQ:TENX) - Defense World
TherapeuticsMD Inc. stock underperforms Tuesday when compared to competitors - MarketWatch
Tencent Music Entertainment Group (NYSE:TME) Shares Gap Up to $10.18 - MarketBeat
Tencent Music Entertainment Group Target of Unusually High Options Trading (NYSE:TME) - MarketBeat
Farallon Capital Management LLC Buys Shares of 2,000 TransMedics Group, Inc. (NASDAQ:TMDX) - Defense World
Tencent Music Entertainment Group (TME): Among the Worst Affordable Stocks to Buy Under $10 - Insider Monkey
Transmedics Group Inc [TMDX] Stock sold by Insider Hassanein Waleed H for $1.32 million - Knox Daily
Finanzdaten der Tenax Therapeutics Inc-Aktie (TENX)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.09%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):